Xeris Biopharma Holdings, Inc. XERS
Xeris Biopharma Holdings, Inc. along with its subsidiaries, is referenced herein as the "Company", "Xeris", "Xeris Biopharma", "we" or "our". Throughout this document, unless otherwise noted, references to Gvoke include Gvoke PFS, Gvoke HypoPen, and Gvoke Kit.
We are a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. We offer Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis ("PPP"). We are advancing our Phase 3-ready pipeline product, XP-8121, once-weekly subcutaneous ("SC") levothyroxine, which leverages our proprietary technology XeriSol.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $291.8M | $203.1M | $163.9M | $110.2M | $49.6M | $20.2M | — |
| R&D | $31.2M | $25.6M | $22.3M | $21.0M | $25.2M | $20.9M | — |
| SG&A | $182.4M | $163.5M | $146.1M | $137.7M | $125.7M | $73.7M | — |
| Operating income | $24.9M | -$33.6M | -$44.0M | -$81.9M | -$115.2M | -$83.5M | — |
| Interest expense | $29.1M | $30.5M | $26.6M | $14.1M | $7.2M | $10.7M | — |
| Pre-tax income | $554.0K | -$57.1M | -$63.5M | -$96.1M | -$122.7M | -$91.0M | — |
| Income tax | $0 | $2.3M | $1.2M | $1.4M | $0 | $110.0K | — |
| Net income | $554.0K | -$54.8M | -$62.3M | -$94.7M | -$122.7M | -$91.1M | — |
| EPS, basic | 0.00 | -0.37 | -0.45 | -0.70 | -1.55 | — | — |
| EPS, diluted | 0.00 | -0.37 | -0.45 | -0.70 | -1.55 | -2.14 | — |
| Shares, diluted (wtd. avg.) | 172.7M | 146.8M | 137.7M | 135.6M | 79.0M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $111.0M | $71.6M | $67.4M | $126.3M | $67.3M | $37.6M | $19.5M |
| Short-term investments | — | $0 | $5.0M | $0 | $35.2M | $96.2M | — |
| Receivables | $51.0M | $40.4M | $39.2M | $30.8M | $17.5M | $6.9M | — |
| Inventory | $68.7M | $48.2M | $38.8M | $24.7M | $18.1M | $8.4M | — |
| Total current assets | $240.3M | $167.7M | $156.3M | $186.8M | $142.6M | $152.2M | — |
| Property, plant and equipment | $4.9M | $5.6M | $6.0M | $5.5M | $6.6M | $6.7M | — |
| Goodwill | $22.9M | $22.9M | $22.9M | $22.9M | $22.9M | $0 | — |
| Other intangibles | $88.1M | $98.9M | $109.8M | $120.6M | $131.4M | $0 | — |
| Total assets | $383.5M | $323.1M | $322.6M | $344.5M | $304.4M | $159.2M | — |
| Accounts payable | $3.1M | $2.3M | $11.6M | $4.6M | $8.9M | $3.1M | — |
| Short-term debt | $0 | $15.1M | $0 | — | — | — | — |
| Total current liabilities | $109.6M | $100.4M | $95.2M | $73.6M | $79.0M | $28.2M | — |
| Long-term debt | $220.3M | $217.0M | $190.9M | $187.1M | $88.1M | $87.0M | — |
| Total liabilities | $369.8M | $352.7M | $329.4M | $299.3M | $209.1M | $125.4M | — |
| Retained earnings | -$671.3M | -$671.9M | -$617.0M | -$554.8M | -$460.1M | -$337.4M | — |
| Total equity | $13.7M | -$29.6M | -$6.8M | $45.2M | $95.2M | $33.8M | $14.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $28.6M | -$37.0M | -$47.0M | -$102.9M | -$95.5M | -$80.6M | — |
| Depreciation and amortisation | $1.3M | $1.2M | $1.5M | $1.4M | $1.3M | $1.5M | — |
| Stock-based compensation | $22.4M | $18.4M | $10.7M | $12.2M | $11.4M | $8.3M | — |
| Capital expenditure | — | — | — | — | $1.1M | $377.0K | — |
| Investing cash flow | -$696.0K | $4.9M | -$6.0M | $34.5M | $98.0M | -$27.4M | — |
| Financing cash flow | $11.4M | $36.2M | -$1.6M | $127.5M | $27.2M | $126.1M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001867096-26-000021.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $20.2M | $49.6M | $110.2M | $163.9M | $203.1M | $291.8M |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$91.1M | -$122.7M | -$94.7M | -$62.3M | -$54.8M | $554.0K |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Unregistered share sale Item 3.02
- Other event Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Officer or director change Item 5.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |